相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study
Y. Sun et al.
LUNG CANCER (2013)
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
J. Wolchok
ANNALS OF ONCOLOGY (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update
Ayodele Ayoola et al.
CANCER INVESTIGATION (2012)
Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations
Woody Han et al.
CANCER LETTERS (2012)
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer
David R. Spigel et al.
CLINICAL LUNG CANCER (2012)
The battle against ALK resistance: successes and setbacks
Claudia Voena et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer
Paolo Ceppi et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib Versus Placebo in Patients With Advanced Non-Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)
Jin Soo Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
Rodryg Ramlau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Maintenance Therapy and Advanced Non-Small-Cell Lung Cancer A Skeptic's View
Martin J. Edelman et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Cesare Gridelli et al.
LUNG CANCER (2012)
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer?
Jong-Mu Sun et al.
LUNG CANCER (2012)
Chipping away at the lung cancer genome
William Pao et al.
NATURE MEDICINE (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
L. V. Sequist et al.
ANNALS OF ONCOLOGY (2011)
Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features
Tokujiro Yano et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
Richard H. de Boer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
Wolfram Brugger et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Harboring BRAF Mutations
Antonio Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paul K. Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
Ulrich Gatzemeier et al.
LANCET ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
Dae Ho Lee et al.
CLINICAL CANCER RESEARCH (2010)
Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Non-Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab
Ronan J. Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
Glenwood D. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
Tito Fojo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer A Systematic Review with Meta-Analysis
Ping Zhan et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu et al.
LANCET (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
Riichiroh Maruyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort
Michele Beau-Faller et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
DNA methylation markers and early recurrence in stage I lung cancer
Malcolm V. Brock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson et al.
CANCER RESEARCH (2006)
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: Results of a phase II-III study
A Paccagnella et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America
C Ho et al.
LUNG CANCER (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Structural and functional analysis of the costimulatory receptor programmed death-1
XW Zhang et al.
IMMUNITY (2004)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer - A meta-analysis
C Delbaldo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
M Ronson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial
P Bonomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)